-+ 0.00%
-+ 0.00%
-+ 0.00%

Ultragenyx settles DOJOLVI patent suit, grants Esjay generic entry from 2033

PUBT·08/11/2026 12:32:17
Listen to the news
Ultragenyx settles DOJOLVI patent suit, grants Esjay generic entry from 2033
  • Ultragenyx settled New Jersey patent litigation tied to Esjay’s ANDA for a generic version of DOJOLVI (triheptanoin) oral liquid.
  • Deal grants Esjay a non-exclusive, royalty-free license to launch a generic starting Jan. 1, 2033.
  • Launch shifts to July 1, 2033 if DOJOLVI receives pediatric exclusivity, subject to customary conditions.
  • Patent suits against other DOJOLVI ANDA filers remain pending in the same court.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-343525), on August 11, 2026, and is solely responsible for the information contained therein.